Menu
Back to Journals » OncoTargets and Therapy » Volume 7
Profile of selumetinib and its potential in the treatment of melanoma
Authors Kim DW, Patel S
Received 4 April 2014
Accepted for publication 1 July 2014
Published 19 September 2014 Volume 2014:7 Pages 1631—1639
DOI https://doi.org/10.2147/OTT.S51596
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Dae Won Kim, Sapna P Patel
Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Abstract: The mitogen-activated protein kinase (MAPK) pathway is a critical oncogenic driver signal in a number of malignancies. The discovery of activating mutations in the MAPK pathway has led to the development of MAPK pathway inhibitors. Selumetinib is a potent and selective inhibitor of MEK1 and MEK2, which are essential downstream molecules in the MAPK pathway. Several preclinical and clinical studies have demonstrated the promising antitumor activity of selumetinib. In this review, we discuss the MAPK pathway in melanoma and summarized data from preclinical and clinical studies of selumetinib for advanced melanoma.
Keywords: selumetinib, MEK inhibitor, melanoma, uveal melanoma
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.